Clinical outcome of stage III non-small-cell lung cancer patients after definitive radiotherapy

Lung

Volumn 186, Issue 2, 2008, Pages 91-96

  Nakamura, Tatsuya ^a   Fuwa, Nobukazu ^a   Kodaira, Takeshi ^a   Tachibana, Hiroyuki ^a   Tomoda, Takuya ^a   Nakahara, Rie ^a   Inokuchi, Haruo ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemotherapy; Lung cancer; Radiotherapy; Survival analysis

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION PNEUMONIA; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM STAGING; PROGNOSIS; RADIATION PNEUMONITIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINBLASTINE; VINDESINE;

EID: 43349106307     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00408-007-9063-5     Document Type: Article

References (15)

1. Holmes EC (1991) Surgical adjuvant therapy of non-small-cell lung cancer. Lung Cancer 7:71-76
2. Perez CA, Stanley K, Grundy G, Hanson W, Rubin P, Kramer S, Brady LW, Marks JE, Perez-Tamayo R, Brown GS, Concannon JP, Rotman M (1982) Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung: report by the Radiation Therapy Oncology Group. Cancer 50:1091-1099
3. Pritchard RS, Anthony SP (1997) Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 125:723-729
4. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909
5. Sause W, Kolesar P, Taylor S IV, Johnson D, Livingston R, Komaki R, Emami B, Curran W Jr, Byhardt R, Dar AR, Turrisi A 3rd (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358-364
6. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
7. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699
8. Furuse K, Hosoe S, Masuda N, Sugiura T, Yokota S, Ohbayashi K, Okazaki M, Nakamura S, Tohda Y, Sawa S, Kamei T, Takada M (2000) Impact of tumor control on survival in unresectable stage III non-small cell lung cancer (NSCLC) treated with concurrent thoracic radiotherapy (TRT) and chemotherapy (CT). Proc Am Soc Clin Oncol 19:1893
9. Curran W Jr, Scott C, Langer C, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal S, Byhardt R, Sause W, Cox J (2000) Phase III Comparison of sequential vs concurrent chemoradiation for patients (Pts) with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 19:1891
10. Albain KS, Crowley JJ, Turrisi AT 3rd, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB (2002) Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 20:3454-3460
11. Jeremic B, Milicic B, Acimovic L, Milisavljevic S (2005) Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer: long-term results of a phase II study. J Clin Oncol 23:1144-1451
12. Hayakawa K (2003) Radiation therapy in the treatment of lung cancer. Nippon Igaku Hoshasen Gakkai Zasshi 63:533-538
13. Tsujino K, Hirota S, Endo M, Obayashi K, Kotani Y, Satouchi M, Kado T, Takada Y (2003) Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 55:110-115
14. Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, Perez CA (1999) Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45:323-329
15. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR; American Society of Clinical Oncology (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330-353